Familial Amyloid Polyneuropathy Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Familial Amyloid Polyneuropathy Market
Familial Amyloid Polyneuropathy Market: By Type (FAP-I, FAP-II, FAP-III, and FAP-IV); By Category (Peripheral Sensorimotor Polyneuropathy, and Autonomic Nervous System Dysfunction) & By Region (Europe, Asia-Pacific, Others)-Forecast (2016-2021)
Report Code : HCR 0210
Updated Date: 28 January, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Symptoms for the disorder include limb weakness, and loss of sensation in case of peripheral neuropathy, bowel disturbance and sexual dysfunction in case of autonomic neuropathy. The most successful cure for the disorder is liver transplant, however Europe has approved a drug named Vyndaqel (tafamidis) by Pfizer Inc. and is under Phase III clinical trials to seek U.S. FDA approval. Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market. In addition, increase in adoption of familial amyloid polyneuropathy drugs, and emerging economies such as China, India and others will create new opportunities for the familial amyloid polyneuropathy market. However, higher cost of the research and development, and treatment, and stringent government regulations are the key restraints for the familial amyloid polyneuropathy market.

This report identifies the global familial amyloid polyneuropathy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to the global familial amyloid polyneuropathy market.

Familial Amyloid Polyneuropathy Market

Geographically, Europe dominates the familial amyloid polyneuropathy market, and Asia Pacific is projected to have the fastest growth, owing to rapidly increasing aging population and modernizing healthcare infrastructure in this region. Among all the categorises, peripheral sensorimotor polyneuropathy has the highest market share in the familial amyloid polyneuropathy market.

This report segments familial amyloid polyneuropathy market on the basis of type, category, and regional market as follows:
  • Familial Amyloid Polyneuropathy Market, By Type: Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III), and Familial Amyloid Polyneuropathy-IV (FAP-IV)
  • Familial Amyloid Polyneuropathy Market, By Category: Peripheral Sensorimotor Polyneuropathy, and Autonomic Nervous System Dysfunction
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the familial amyloid polyneuropathy market. Some of the major companies’ profiles in detail are as follows:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals
1. Familial Amyloid Polyneuropathy Market –Overview
2. Executive Summary
3. 
Familial Amyloid Polyneuropathy Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Familial Amyloid Polyneuropathy Market–Forces
   4.1. Drivers
      4.1.1. Development of new drugs for treatment of familial amyloid polyneuropathy
      4.1.2. Rise in the prevalence of familial amyloid polyneuropathy
   4.2. Restraints
      4.2.1. Higher cost of research and development, and treatment
      4.2.2. Stringent government regulations
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of familial amyloid polyneuropathy drugs
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Familial Amyloid Polyneuropathy Market, By Type 
   5.1. Familial Amyloid Polyneuropathy-I (FAP-I)
   5.2. Familial Amyloid Polyneuropathy-II (FAP-II)
   5.3. Familial Amyloid Polyneuropathy-III (FAP-III)
   5.4. Familial Amyloid Polyneuropathy-IV (FAP-IV)
6. Familial Amyloid Polyneuropathy Market, By Category
   6.1. Peripheral Sensorimotor Polyneuropathy
   6.2. Autonomic Nervous System Dysfunction
7. Familial Amyloid Polyneuropathy Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Familial Amyloid Polyneuropathy – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   9.1. Pfizer Inc.
   9.2. GlaxoSmithKline plc
   9.3. Ionis Pharmaceuticals
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll